Serum micrornas as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy

HIGHLIGHTS

• who: Bartłomiej Tomasik MD and PhD from the This study was funded by the statutory funds of Medical University of have published the paper: Serum MicroRNAs as Xerostomia Biomarkers in Patients With Oropharyngeal Cancer Undergoing Radiation Therapy, in the Journal: (JOURNAL)
• what: As stressed by the authors of this work, because irradiation of normal tissue is inevitable, RT is characterized by a distinct toxicity profile. For this study, the primary endpoint was defined as severe (grade ≥3) xerostomia at 3 months after RT based on the EORTC QLQ-H and amp;N35 questionnaire result . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.